I3LUNG Study Using AI to Predict Immunotherapy Success in Adults with Advanced Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are developing a medical device using artificial intelligence to predict how well immunotherapy works in patients with non-small cell lung cancer NSCLC. The project combines data from past patients retrospective study and ongoing data collection from current patients prospective study. The aim is to create predictive models that help personalize treatment decisions, improve patient care, and reduce side effects and healthcare costs. The retrospective study includes data from over 2,000 patients, including clinical information and imaging scans like CT and PET, to build an initial predictive model. The prospective study collects detailed multi-omics data from about 200 patients to validate and improve this model, leading to a final tool called PDSS. This AI-based tool will help clinicians make better-informed treatment decisions by providing easy access to predictive information. Participants in the prospective study will provide biological samples for multi-omics analysis and undergo assessments during their treatment. Researchers will evaluate treatment response at 8 weeks using imaging scans and monitor progression-free survival and overall survival for up to 10 years. The project also aims to develop patient decision aids to support shared decision-making and improve communication between patients and doctors throughout the study duration.

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy